{"entity":{"id":"iteria-biopharma","kind":"company","name":"Iteria Biopharma","aka":["ITERIA BIOPHARMA, S.L."],"tldr":"Iteria Biopharma is a Galician company designing new small-molecule medicines for cancer. Its first, ITR-251, is aimed at prostate cancer that has spread and stopped responding to hormone therapy, and is due to start its first human trial.","summary":"Iteria Biopharma, S.L. is a precision oncology drug discovery company based in Touro, A Coruña, in Galicia, Spain. It presented itself as a new Galician biotech in December 2024, founded by the chemistry company GalChimia (Carme Pampín), Julio Castro of Palobiofarma, and Ramon Bosser, who is chief executive; it was set up to take over GalChimia's MAOPROST project. It designs first-in-class new chemical entities. Its lead, ITR-251, is for metastatic castration-resistant prostate cancer, and two early research programmes address pancreatic, colorectal and lung cancer. A phase 1/1b study (NCT07870096) is registered to test ITR-251 first in advanced solid tumours and then in metastatic castration-resistant prostate cancer together with androgen receptor pathway inhibitors. In April 2026 it closed a EUR 5 million seed round led by Inveready through Inveready Biotech IV, with Xunta de Galicia co-investing through Xesgalicia alongside existing investors and the founders.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://iteriabiopharma.com/"},{"label":"Company launch announcement, December 2024","url":"https://iteriabiopharma.com/2024/12/04/iteria-biopharma-the-new-galician-biotech-focused-on-the-discovery-of-precision-drugs-for-cancer-treatment/"},{"label":"Seed round release, April 2026","url":"https://iteriabiopharma.com/2026/04/16/iteria-biopharma-closes-a-e5m-seed-round/"},{"label":"ClinicalTrials.gov: ITR-251 phase 1/1b (NCT07870096)","url":"https://clinicaltrials.gov/study/NCT07870096"}],"tags":[],"related":[],"cancers":["prostate-mcrpc","pancreatic","colorectal","nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; the company announced itself in a release datelined 3 December 2024. ITR-251's molecular target is not disclosed, so no target is linked. No technology is linked: ITR-251's mechanism is not disclosed, and the registered trial combines it with androgen receptor pathway inhibitors without describing it as one. ClinicalTrials.gov gives a start in October 2026, while the seed release said the first phase 1 trial would start in early 2027. Parts of the company website still carry template placeholder text."],"hq":"Touro, Galicia","country":"ES","companyType":"biotech","website":"https://iteriabiopharma.com/","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2026,"source":"https://iteriabiopharma.com/2026/04/16/iteria-biopharma-closes-a-e5m-seed-round/","note":"EUR 5 million; led by Inveready (Inveready Biotech IV) with Xesgalicia, existing investors and the founders; no USD figure stated"}]},"route":"/companies/iteria-biopharma/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}]}}